Non-small cell lung cancer metastatic
RecruitingPhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
Phase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
- Disease:Non-small cell lung cancer metastatic
- Substances:BMS-986340Carboplatin+5
France- Participants:18–64 years · 65+ years
- Substances:BMS-986340
- Sponsor:Bristol-Myers Squibb Services Unlimited Company














